Inmune Bio (INMB) Asset Utilization Ratio (2021 - 2025)
Inmune Bio (INMB) posted Asset Utilization Ratio of 0.0 for Q4 2025, up 17.74% sequentially from 0.0 in Q1 2025, and up 401.91% YoY from 0.0 in Q4 2024.
Inmune Bio (INMB) Asset Utilization Ratio (2021 - 2025) Analysis & Trends
Inmune Bio has reported Asset Utilization Ratio for 5 years, with the latest figure at 0.0 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 401.91% year-over-year to 0.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0 (up 401.91% YoY) and the FY2025 annual result came in at 0.0, up 379.56% from the prior year.
- Asset Utilization Ratio advanced to 0.0 in Q4 2025 per INMB's latest filing, from 0.0 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.01 in Q3 2022 and troughed at 0.0 in Q2 2021.
- A 5-year average of 0.0 and a median of 0.0 in 2021 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2022 and 2024: Asset Utilization Ratio surged 6084.1% in 2022, then slumped 88.29% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.0 in 2021, then surged by 159.06% to 0.0 in 2022, then sank by 42.67% to 0.0 in 2023, then tumbled by 88.29% to 0.0 in 2024, then surged by 401.91% to 0.0 in 2025.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.0, 0.0, and 0.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 0.13 |
| 10 | Inmune Bio | 61.32 Mn | 42.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.01 |
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.00 |
| Mar 31, 2021 | 0.00 |